At the crossroads: The intersection of substance use disorders, anxiety disorders, and posttraumatic stress disorder topical collection on substance use and related disorders

Current Psychiatry Reports

Volumn 16, Issue 11, 2014, Pages 1-9

  Ruglass, Lesia M ^a   Lopez Castro, Teresa ^a   Cheref, Soumia ^a   Papini, Santiago ^a   Hien, Denise A ^a,b  

^a CITY COLLEGE OF NEW YORK   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Anxiety disorders; Comorbidity; Integrated treatment; Posttraumatic stress disorder; Substance use disorder

Indexed keywords

DESIPRAMINE; NALTREXONE; PAROXETINE; PROPRANOLOL; SERTRALINE;

ADDICTION; ALCOHOL USE DISORDER; ALCOHOLISM; ANXIETY; ANXIETY DISORDER; ANXIETY SENSITIVITY; ATTENTIONAL BIAS; BEHAVIOR THERAPY; COGNITIVE THERAPY; COMORBIDITY; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; HEALTH BELIEF; HUMAN; INTEGRATED THERAPY; MEMORY CONSOLIDATION; META ANALYSIS (TOPIC); NEUROBIOLOGY; NEUROSCIENCE; OUTCOME EXPECTANCY; PARALLEL INTERVENTION STRATEGY; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SELF MEDICATION HYPOTHESIS; SEQUENTIAL INTERVENTION STRATEGY; SEX DIFFERENCE; SUBSTANCE ABUSE; SUBSTANCE INDUCED HYPOTHESIS; THEORETICAL MODEL; THERAPY; TRANSLATIONAL RESEARCH;

EID: 84907166253     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0505-5     Document Type: Review

References (95)

1. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807-16.
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-27.
3. Gielen N, Havermans RC, Tekelenburg M, et al. Prevalence of post-traumatic stress disorder among patients with substance use disorder: It is higher than clinicians think it is. Eur J Psychotraumatol. 2012;3.
4. Driessen M, Schulte S, Luedecke C, et al. Trauma and PTSD in patients with alcohol, drug, or dual dependence: A multi-center study. Alcohol Clin Exp Res. 2008;32(3):481-8.
5. Boschloo L, Vogelzangs N, Smit JH, et al. Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders: findings from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2011;131(1):233-42.
6. Smith JP, Randall CL. Anxiety and alcohol use disorders: comorbidity and treatment considerations. Alcohol Res. 2012;34(4):414-31.
7. McCauley JL, Killeen T, Gros DF, et al. Posttraumatic stress disorder and co-occurring substance use disorders: Advances in assessment and treatment. Clin Psychol. 2012;9(3):283-304.
8. Breslau N, Davis GC, Schultz LR. Posttraumatic stress disorder and the incidence of nicotine, alcohol, and other drug disorders in persons who have experienced trauma. Arch Gen Psychiatry. 2003;60(3):289-94.
9. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25(3):456-65.
10. McLean CP, Asnaani A, Litz BT, et al. Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011;45(8):1027-35.
11. Wolitzky-Taylor K, Operskalski JT, Ries R, et al. Understanding and treating comorbid anxiety disorders in substance users: Review and future directions. J Addict Med. 2011;5(4):233-47.
12. Brady KT, Back SE. Childhood trauma, posttraumatic stress disorder, and alcohol dependence. Alcohol Res. 2012;34(4):408-13.
13. Buckner JD, Heimberg RG, Ecker AH, et al. A biopsychosocial model of social anxiety and substance use. Depress Anxiety. 2013;30(3):276-84.
14. Marmorstein NR. Anxiety disorders and substance use disorders: Different associations by anxiety disorder. J Anxiety Disord. 2012;26(1):88-94.
15. Crum RM, La Flair L, Storr CL, et al. Reports of drinking to self-medicate anxiety symptoms: Longitudinal assessment for subgroups of individuals with alcohol dependence. Depress Anxiety. 2013;30(2):174-83. This study assessed drinking to self-medicate anxiety and its association with the occurrence or persistence of alcohol dependence in population-based longitudinal samples, and associations within demographic and clinical subgroups.
16. Naifeh JA, Tull MT, Gratz KL. Anxiety sensitivity, emotional avoidance, and PTSD symptom severity among crack/cocaine dependent patients in residential treatment. Cognit Ther Res. 2012;36(3):247-57.
17. Bacon AK, Ham LS. Attention to social threat as a vulnerability to the development of comorbid social anxiety disorder and alcohol use disorders: An avoidance-coping cognitive model. Addict Behav. 2010;35(11):925-39.
18. Bar-Haim Y, Lamy D, Pergamin L. Threat-related attentional bias in anxious and nonanxious individuals: A meta-analytic study. Psychol Bull. 2007;133(1):1-24.
19. Field M, Marhe R, Franken IH. The clinical relevance of attentional bias in substance use disorders. CNS Spectr. 2014;19(03):225-30.
20. Bardeen JR, Orcutt HK. Attentional control as a moderator of the relationship between posttraumatic stress symptoms and attentional threat bias. J Anxiety Disord. 2011;25(8):1008-18.
21. Tull MT, McDermott MJ, Gratz KL, et al. Cocaine-related attentional bias following trauma cue exposure among cocaine dependent in-patients with and without post-traumatic stress disorder. Addiction. 2011;106(10):1810-8.
22. Reiss S, McNally RJ. (1985). Expectancy model of fear. In: Reiss S, Bootzin RR, editors. Theoretical issues in behavior therapy. San Diego: Academic; 1985. pp. 107-121.
23. Chandley RB, Luebbe AM, Messman-Moore TL, et al. Anxiety sensitivity, coping motives, emotion dysregulation, and alcohol-related outcomes in college women: A moderated-mediation model. J Stud Alcohol Drugs. 2014;75(1):83-92.
24. Elwood LS, Hahn KS, Olatunji BO, et al. Cognitive vulnerabilities to the development of PTSD: A review of four vulnerabilities and the proposal of an integrative vulnerability model. Clin Psychol Rev. 2009;29(1):87-100.
25. DeMartini KS, Carey KB. The role of anxiety sensitivity and drinking motives in predicting alcohol use: A critical review. Clin Psychol Rev. 2011;31(1):169-77.
26. Gillihan SJ, Farris SG, Foa EB. The effect of anxiety sensitivity on alcohol consumption among individuals with comorbid alcohol dependence and posttraumatic stress disorder. Psychol Addict Behav. 2011;25(4):721-6.
27. Carmody TP, McFall M, Saxon AJ, et al. Smoking outcome expectancies in military veteran smokers with posttraumatic stress disorder. Nicotine Tob Res. 2012;14(8):919-26.
28. Goldsmith AA, Thompson RD, Black JJ, et al. Drinking refusal self-efficacy and tension-reduction alcohol expectancies moderating the relationship between generalized anxiety and drinking behaviors in young adult drinkers. Psychol Addict Behav. 2012;26(1):59-67.
29. Pasche S. Exploring the comorbidity of anxiety and substance use disorders. Curr Psychiatry Rep. 2012;14(3):176-81.
30. Norman SB, Myers US, Wilkins KC, et al. Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder. Neuropharmacology. 2012;62(2):542-51. A systematic review is provided regarding the neurobiological mechanisms implicated in the development and maintenance of comorbid PTSD and substance use disorder.
31. Koob GF, Zorrilla EP. Neurobiological mechanisms of addiction: Focus on corticotropin-releasing factor. Curr Opin Investig Drugs. 2010;11(1):1-16.
32. Hien DA, Litt LC, Cohen LR, et al. Trauma services for women in substance abuse treatment: An integrated approach. Washington, DC: American Psychological Association; 2008.
33. Pitman RK, van der Kolk BA, Orr SP, et al. Naloxone-reversible analgesic response to combat related stimuli in posttraumatic stress disorder: A pilot study. Arch Gen Psychiatry. 1990;47(6):541-4.
34. Ouimette P, Read JP, Wade M, et al. Modeling associations between posttraumatic stress symptoms and substance use. Addict Behav. 2010;35:64-7.
35. Najt P, Fusar-Poli P, Brambilla P. Co-occurring mental and substance abuse disorders: A review on the potential predictors and clinical outcomes. Psychiatry Res. 2011;30:159-64.
36. Hien DA, Jiang H, Campbell A, et al. Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network. Am J Psychiatry. 2010;167(1):95-101.
37. Mills KL, Teesson M, Back SE, et al. Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: A randomized controlled trial. JAMA. 2012;308(7):690-9. This article is the first randomized clinical trial of an integrated, prolonged exposure-based treatment for PTSD and SUD and demonstrated effectiveness of prolonged exposure for reduction of PTSD symptoms without negative impact on SUD outcomes.
38. Sannibale C, Teesson M, Creamer M, et al. Randomized controlled trial of cognitive behaviour therapy for comorbid post-traumatic stress disorder and alcohol use disorders. Addiction. 2013;108(8):1397-410.
39. van Dam D, Vedel E, Ehring T, et al. Psychological treatments for concurrent posttraumatic stress disorder and substance use disorder: A systematic review. Clin Psychol Rev. 2012;32(3):202-14.
40. Najavits LM, Hien D. Helping vulnerable populations: A comprehensive review of the treatment outcome literature on substance use disorder and PTSD. J Clin Psychol. 2013;69(5):433-79.
41. Back SE, Brady KT, Sonne S, et al. Symptom Improvement in Co-Occurring PTSD and Alcohol Dependence. J Nerv Ment Dis. 2006;194(9):690-6.
42. Najavits LM. Treatment of posttraumatic stress disorder and substance abuse: Clinical guidelines for implementing Seeking Safety therapy. Alcohol Treat Q. 2004;22:43-62.
43. Burns MN, Lehman KA, Milby JB, et al. Do PTSD symptoms and course predict continued substance use for homeless individuals in contingency management for cocaine dependence? Behav Res Ther. 2010;48(7):588-98.
44. Morgan-Lopez AA, Saavedra LM, Hien DA, et al. Indirect Effects of Seeking Safety on Substance Use Outcomes: Overall and Attendance Class-Specific Effects. Am J Addict. 2014;23(3):218-25.
45. Hien DA, Cohen LR, Miele GM, et al. Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry. 2004;161(8):1426-32.
46. Hien DA, Wells EA, Jiang H, et al. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol. 2009;77(4):607-19.
47. Foa EB, Keane TM, Friedman MJ, et al. Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies. 2nd ed. New York: Guilford; 2008.
48. Foa EB, Hembree EA, Rothbaum BO. Prolonged exposure therapy for PTSD: Emotional processing of traumatic experiences: Therapist guide. New York: Oxford University Press; 2007.
49. Allen JP, Mattson ME, Miller WR, Tonigan JS, Connors GJ, Rychtarik RG, et al. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58(1):7-29.
50. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179-87.
51. Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety disorders: A review of meta-analytic findings. Psychiatr Clin North Am. 2010;33(3):557-77.
52. Baillie AJ, Stapinski L, Crome E, et al. Some new directions for research on psychological interventions for comorbid anxiety and substance use disorders. Drug Alcohol Rev. 2010;29(5):518-24.
53. Baker AL, Thornton LK, Hiles S, et al. Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: A systematic review. J Affect Disord. 2012;139(3):217-29.
54. Hesse M. Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature. BMC Psychiatry. 2009;9(1):6.
55. Schade A, Marquenie LA, van Balkom AJ, et al. The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. Alcohol Clin Exp Res. 2004;29(5):794-800.
56. Kushner MG, Donahue C, Sletten S, et al. Cognitive behavioral treatment of comorbid anxiety disorder in alcoholism treatment patients: Presentation of a prototype program and future directions. J Ment Health. 2006;15(6):697-707.
57. Bowen RC, D'Arcy C, Keegan D, et al. A controlled trial of cognitive behavioral treatment of panic in alcoholic inpatients with comorbid panic disorder. Addict Behav. 2000;25(4):593-7.
58. Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments. Alcohol Clin Exp Res. 2001;25(2):210-20.
59. Toneatto T. Cognitive versus behavioral treatment of concurrent alcohol dependence and agoraphobia: a pilot study. Addict Behav. 2005;30(1):115-25.
60. Hobbs JD, Kushner MG, Lee SS, et al. Meta-analysis of supplemental treatment for depressive and anxiety disorders in patients being treated for alcohol dependence. Am J Addict. 2011;20(4):319-29.
61. Zvolensky MJ, Brandt C, Bernstein A. Panic psychopathology and substance use disorders. Ann Psychother Integr Health. 2011;14(1):28-41.
62. Kushner MG, Maurer EW, Thuras P, et al. Hybrid cognitive behavioral therapy versus relaxation training for co-occurring anxiety and alcohol disorder: a randomized clinical trial. J Consult Clin Psychol. 2013;81(3):429-42. This randomized clinical trial examined the efficacy of an integrated therapy for co-occurring AD and AUD. Above and beyond anxiety reduction, results implicated the significant role of addressing the associations between the disorders in improved outcomes for co-occurring AD and AUD.
63. Brady KT, Sonne S, Anton RF, et al. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005;29(3):395-401.
64. Petrakis IL, Ralevski E, Desa N, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology. 2012;37(4):996-1004.
65. Foa EB, Yusko DA, McLean CP, et al. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: A randomized clinical trial. JAMA. 2013;310(5):488-95. This article presents findings from the first randomized clinical trial to test the efficacy of a combined pharmacotherapy and psychotherapy approach for comorbid PTSD and AUD.
66. Morrison FG, Ressler KJ. From the neurobiology of extinction to improved clinical treatments. Depression Anxiety. 2014;31(4):279-90.
67. Kiefer F, Dinter C. New approaches to addiction treatment based on learning and memory. In: Sommer WH, Spanagel R, editors. Behavioral Neurobiology of Alcohol Addiction. 1st ed. Berlin: Springer; 2013. p. 671-84.
68. Olive, MF, Kalivas, PW. Conditioning of addiction. In: Johnson BA, ed. Addiction Medicine. 1st edn. New York, NY:Springer;2011:159-178).
69. VanElzakker MB, Kathryn-Dahlgren M, Caroline-Davis F, et al. From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders. Neurobiol Learn Mem. 2013;113:3-18.
70. Delamater AR, Westbrook RF. Psychological and neural mechanisms of experimental extinction: A selective review. Neurobiol Learn Mem. 2014;108:38-51.
71. Kaplan GB, Heinrichs SC, Carey RJ. Treatment of addiction and anxiety using extinction approaches: neural mechanisms and their treatment implications. Pharmacol Biochem Behav. 2011;97(3):619-25.
72. Peters J, Kalivas PW, Quirk GJ. Extinction circuits for fear and addiction overlap in prefrontal cortex. Learn Mem. 2011;16(5):279-88.
73. Kantak KM, Nic-Dhonnchadha BA. Pharmacological enhancement of drug cue extinction learning: translational challenges. Ann N Y Acad Sci. 2011;1216(1):122-37.
74. Hofmann SG, Fang A, Gutner CA. Cognitive enhancers for the treatment of anxiety disorders. Restor Neurol Neurosci. 2014;32(1):183-95.
75. Jones R. Learning and memory: Learning to forget. Nat Rev Neurosci. 2013;14(4):228-9.
76. Alberini CM, LeDoux JE. Memory reconsolidation. Curr Biol. 2013;23(17):746-50.
77. Schwabe L, Nader K. Pruessner, JC. Biol Psychiatry: Reconsolidation of Human Memory, Brain Mechanisms and Clinical Relevance; 2014. doi: 10.1016/j.biopsych.2014.03.008.
78. Yates D. Learning and memory: Unlearning fear. Nat Rev Neurosci. 2014;15:134-5.
79. Torregrossa MM, Taylor JR. Learning to forget: manipulating extinction and reconsolidation processes to treat addiction. Psychopharmacology. 2013;226(4):659-72.
80. Merlo E, Milton AL, Goozée ZY, Theobald DE, et al. Reconsolidation and Extinction Are Dissociable and Mutually Exclusive Processes: Behavioral and Molecular Evidence. J Neurosci. 2014;34(7):2422-31.
81. Zhao LY, Sun LL, Shi J, et al. Effects of β-adrenergic receptor blockade on drug-related memory reconsolidation in abstinent heroin addicts. Drug Alcohol Depend. 2011;118(2):224-9.
82. Saladin ME, Gray KM, McRae-Clark AL, et al. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology. 2013;226(4):721-37.
83. Schwabe L, Nader K, Wolf OT, et al. Neural signature of reconsolidation impairments by propranolol in humans. Biol Psychiatry. 2012;71(4):380 - 386.
84. Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci. 2009;12(3):256-8.
85. Sevenster D, Beckers T, Kindt M. Retrieval per se is not sufficient to trigger reconsolidation of human fear memory. Neurobiol Learn Mem. 2012;97(3):338-45.
86. Hoge EA, Worthington JJ, Nagurney JT, et al. Effect of Acute Posttrauma Propranolol on PTSD Outcome and Physiological Responses During Script-Driven Imagery. CNS Neurosci Ther. 2012;18(1):21-7.
87. Schiller D, Monfils MH, Raio CM, et al. Preventing the return of fear in humans using reconsolidation update mechanisms. Nature. 2009;463(7277):49-53.
88. Steinfurth EC, Kanen JW, Raio CM, et al. Young and old Pavlovian fear memories can be modified with extinction training during reconsolidation in humans. Learn Mem. 2014;21(7):338-41.
89. Oyarzún JP, Lopez-Barroso D, Fuentemilla L, et al. Updating fearful memories with extinction training during reconsolidation: a human study using auditory aversive stimuli. PLoS One. 2012;7(6):e38849.
90. Warren VT, Anderson KM, Kwon C, et al. Human fear extinction and return of fear using reconsolidation update mechanisms: The contribution of on-line expectancy ratings. Neurobiol Learn Mem. 2014;113:165-73.
91. Agren T, Engman J, Frick A, et al. Disruption of reconsolidation erases a fear memory trace in the human amygdala. Science. 2012;337(6101):1550-2.
92. Schiller D, Kanen JW, LeDoux JE, et al. Extinction during reconsolidation of threat memory diminishes prefrontal cortex involvement. Proc Natl Acad Sci. 2013;110(50):20040-5.
93. Kindt M, Soeter M. Reconsolidation in a human fear conditioning study: a test of extinction as updating mechanism. Biol Psychol. 2013;92(1):43-50.
94. Golkar A, Bellander M, Olsson A, et al. Are fear memories erasable?-reconsolidation of learned fear with fear-relevant and fear-irrelevant stimuli. Front Behav Neurosci. 2012;6(80):1-10.
95. Xue YX, Luo YX, Wu P, et al. A memory retrieval-extinction procedure to prevent drug craving and relapse. Science. 2012;336(6078):241-5. This was the first study to apply the retreival-extinction procedure within the window of reconsolidation to target drug related cues. Results suggest that the procedure was advantageous in reducing craving and relapse.